Skip to main content
OpenTrials
Completed

NCT Number: NCT04402606

Study on Skin Toxicities Induced by Cancer Treatments

The skin toxicities will be evaluated on patient (male or female) with an indication of cancer treatment in the case of solid tumor of the breast, or lung.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Solid Tumor, Adult Breast Cancer Breast Diseases Breast Neoplasms Lung Cancer Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Skin Diseases Skin and Connective Tissue Diseases Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Institut Curie

Paris, 75, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient, male or female, aged 18 years and older, with a solid tumor breast or lung, localized, locally advanced or not, metastatic or not;
  • Patient in medical oncology consultation requiring systemic anti-tumor therapy (chemotherapy, targeted therapy, hormone therapy, immunotherapy) in neo-adjuvant, adjuvant or metastatic;
  • Treatment planned for a minimum period of 3 months (from the date of inclusion);
  • Having a social security protection;
  • Signed informed consent form of the study.

Exclusion criteria

  • Patient treated for lymphoma, leukemia or inflammatory breast cancer ;
  • Patient with a solid tumour which location is other than breast or lung;
  • Patient with a tumor wound ;
  • Patient with a general condition > 2 at baseline (ECOG classification) ;
  • Patient receiving anti-tumor treatment with radiotherapy exclusively or associated with concomitant radiotherapy ;
  • Patient unable to receive information about the study and to give consent ;
  • Persons deprived of liberty or guardianship ;
  • Impossible submission to study procedures for geographical or psychological reasons.

Treatment and study plan

Evaluation on skin toxicities

Other

Measurements will be carried out using specific tools, such as the cutaneous ultrasound system (measurement of the skin layers thicknesses, the cutometer (measurement of the elasticity of the skin), the corneometer (measurement of the hydration of the skin), the pH meter (measuring the pH of the skin), the colorimeter (measuring the color of the skin), the tewameter (measuring the insensible loss of water), the sebometer (measuring sebum).

Primary outcomes

  1. Estimate the rates of severe skin toxicities (grade 2) induced by cancer treatments, at 8 months after the start of treatment.

    Time frame: 8 months

    Severity of cutaneous toxicities at 8 months after the start of treatment (grade > 2 according to the NCI-CTCAE classification version 4.03), induced by the anticancer treatments.

Secondary outcomes

  1. Evaluate the thickness, firmness, tone, viscosity of the skin in case of skin toxicities

    Time frame: 8 months

    The assessments will be performed at day 0 (before the start of the study) and at 1 month (M1), M2, M3, M4 and M8 after the start of treatment. A cutaneous ultrasound system will be used to evaluate thickness of the skin and a cutometer will be used to evaluate firmness, tone and viscosity of the skin. The measurement in millimeters will be used to assess this outcome measure.

  2. Evaluate skin color in case of skin toxicities

    Time frame: 8 months

    The assessments will be performed at day 0 (before the start of the study) and at 1 month (M1), M2, M3, M4 and M8 after the start of treatment. A colorimeter will be used to evaluate skin color. No unit will be used to assess this outcome measure.

  3. Evaluate the skin pH in case of skin toxicities

    Time frame: 8 months

    The assessments will be performed at day 0 (before the start of the study) and at 1 month (M1), M2, M3, M4 and M8 after the start of treatment. A pHmeter will be used to evaluate skin pH. No unit will be used to assess this outcome measure

  4. Evaluate the temperature in case of skin toxicities

    Time frame: 8 months

    The assessments will be performed at day 0 (before the start of the study) and at 1 month (M1), M2, M3, M4 and M8 after the start of treatment. Thermometer will be used to evaluate temperature of the skin. The measurement in degrees Celsius will be used to assess this outcome measure.

  5. Evaluate the quantity of sebum in case of toxicities

    Time frame: 8 months

    The assessments will be performed at day 0 (before the start of the study) and at 1 month (M1), M2, M3, M4 and M8 after the start of treatment. Sebumeter will be used to evaluate quantity of sebum of the skin. The measurement in microgram/centimeter^2 will be used to assess this outcome measure

  6. Evaluate plantar supports in case of toxicities

    Time frame: 8 months

    The assessments will be performed at day 0 (before the start of the study) and at 1 month (M1), M2, M3, M4 and M8 after the start of treatment. Podobarometric platform will be used to evaluate plantar supports. The measurement in N/Centimeter^2 will be used to assess this outcome measure.

  7. Evaluate Skin hydration rate in case of skin toxicities

    Time frame: 8 months

    The assessments will be performed at day 0 (before the start of the study) and at 1 month (M1), M2, M3, M4 and M8 after the start of treatment. Corneometer will be used to evaluate skin hydration rate. No unit will be used to assess this outcome measure.

  8. Evaluate skin elasticity index in case of toxicities

    Time frame: 8 months

    The assessments will be performed at day 0 (before the start of the study) and at 1 month (M1), M2, M3, M4 and M8 after the start of treatment. Cutometer will be used to evaluate skin elasticy. No unit will be used to assess this outcome measure.

  9. Evaluate insensitive loss of water in case of toxicities

    Time frame: 8 months

    The assessments will be performed at day 0 (before the start of the study) and at 1 month (M1), M2, M3, M4 and M8 after the start of treatment. Tewameter will be used to evaluate insensitive loss of water. The measurement in gram/meter^2/hour will be used to assess this outcome measure.

  10. Evaluate variation rate of thickness, firmness, tone, viscosity of the skin over the course of the study

    Time frame: 8 months

    A cutaneous ultrasound system will be used to evaluate thickness of the skin and a cutometer will be used to evaluate firmness, tone and viscosity of the skin. The measurement in millimeters will be used to assess this outcome measure. Variations of thickness, firmness, tone, viscosity of the skin will be calculated according to results obtained at M1, M2,M3, M4 and M8. Results will be compared to initial measures at day 0. Variation rate will be estimated in percentage.

  11. Evaluate variation rate of skin color over the course of the study

    Time frame: 8 months

    A colorimeter will be used to evaluate skin color. No unit will be used to assess this outcome measure. Variations of skin color will be calculated according to results obtained at M1, M2,M3,M4 and M8. Results will be compared to initial measure at day 0. Variation rate will be estimated in percentage.

  12. Evaluate variation rate of skin pH over the course of the study

    Time frame: 8 months

    A pHmeter will be used to evaluate skin pH. No unit will be used to assess this outcome measure. Variations of pH of the skin will be calculated according to results obtained at M1, M2,M3,M4 and M8. Results will be compared to initial measure at day 0. Variation rate will be estimated in percentage

  13. Evaluate variation rate of skin temperature over the course of the study

    Time frame: 8 months

    A thermometer will be used to evaluate skin temperature. The measurement in degrees Celsius will be used to assess this outcome measure. Variations of temperature of the skin will be calculated according to results obtained at M1, M2,M3,M4 and M8. Results will be compared to initial measure at day 0. Variation rate will be estimated in percentage.

  14. Evaluate variation rate of skin sebum quantity over the course of the study

    Time frame: 8 months

    A sebumeter will be used to evaluate quantity of sebum of the skin. The measurement in microgram/centimeter^2 will be used to assess this outcome measure. Variations of quantity of sebum of the skin will be calculated according to results obtained at M1, M2,M3,M4 and M8. Results will be compared to initial measure at day 0. Variation rate will be estimated in percentage.

  15. Evaluate variation rate of plantar supports over the course of the study

    Time frame: 8 months

    A podobarometric platform will be used to evaluate plantar supports. The measurement in N/Centimeter^2 will be used to assess this outcome measure. Variations of plantar supports will be calculated according to results obtained at M1, M2,M3,M4 and M8. Results will be compared to initial measure at day 0. Variation rate will be estimated in percentage.

  16. Evaluate variation rate of skin hydration over the course of the study

    Time frame: 8 months

    A corneometer will be used to evaluate skin hydration rate. No unit will be used to assess this outcome measure. Variations of skin hydration of the skin will be calculated according to results obtained at M1, M2,M3,M4 and M8. Results will be compared to initial measure at day 0. Variation rate will be estimated in percentage.

  17. Evaluate variation rate of skin elasticity over the course of the study

    Time frame: 8 months

    A cutometer will be used to evaluate skin elasticy. No unit will be used to assess this outcome measure. Variations of elasticity of the skin will be calculated according to results obtained at M1, M2,M3,M4 and M8. Results will be compared to initial measure at day 0. Variation rate will be estimated in percentage.

  18. Evaluate variation rate of insensitive loss of water of the skin over the course of the study

    Time frame: 8 months

    A tewameter will be used to evaluate insensitive loss of water. The measurement in gram/meter^2/hour will be used to assess this outcome measure. Variations of insensitive loss of water of the skin will be calculated according to results obtained at M1, M2,M3,M4 and M8. Results will be compared to initial measure at day 0. Variation rate will be estimated in percentage.

  19. Evaluate the consequences of cutaneous toxicities on the patient's therapeutic scheme (hold, dosage reduction, change of molecule);

    Time frame: 8 months

    Number of treatment interruptions or dose changes related to skin toxicities;

  20. To evaluate the quality of life of patients at 8 months;

    Time frame: 8 months

    A questionnaire (Medical Outcome Study Short Form - 36 (MOS SF-36) will be completed by patients. This is a scale allowing to assess health regardless of causal pathology, gender, age and treatment, which is related to patients level of well-being. A score from 0 (poor quality of life) to 100 (very good quality of life) will be given;

  21. Define patient profiles likely to develop severe cutaneous toxicity during their anticancer treatment;

    Time frame: 8 months

    During these assessments, a census of skin toxicities (grade >2) will be carried out according to the NCI-CTCAE version 4.03 classification, and the patient's medical record will be analyzed to determine the predictors of skin toxicities.

Sponsors and collaborators

Lead sponsor

Institut Curie

Other

Registry information

Official study title

DERMACLIC : Study on Skin Toxicities Induced by Cancer Treatments

Acronym: DERMACLIC

Important dates

Study start
2020
Primary completion
2020
Study completion
2024
First posted
May 27, 2020
Registry last updated
Apr 18, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.